My watch list
my.bionity.com  
Login  
More about GILEAD Sciences
  • News

    Gilead Sciences to Acquire MYR GmbH

    Gilead Sciences, Inc. and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €0.3 bn million ( ... more

    Gilead Sciences to Acquire Immunomedics

    Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by ... more

    Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Gilead Sciences, Inc. and Galapagos NV announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and ... more

  • Companies

    GILEAD Sciences GmbH

    Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. Headquartered in Foster City, California, the company has expanded rapidly over the past two de ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE